StocksBeiGene LtdBGNE

BGNE

BeiGene Ltd

224.51 -8.96 (-3.84%)
Preços adiados pelo NASDAQ, em USD Mercado fechado
Negociar
V
224.30
C
225.46
Top
VolatilityAlerts
Free fall: $BGNE (BeiGene Ltd) plummets 7.6%Traduzir
BGNE
BeiGene Ltd
224.30
-8.96 (-3.84%)
Negociar
DeepNews
$BGNE (BeiGene Ltd) BeiGene reports positive findings from Phase 3 trial of tislelizumab + chemotherapy in gastric cancer BeiGene (BGNE) announces positive findings from the Phase 3 RATIONALE 305 trial of tislelizumab versus placebo in combination with chemotherapy as a first-line treatment for seekingalpha.com/news/3790546-beigene-reports-positive-findings-from-phase-3-trial-of-tislelizumab-chemotherapy-in-gastric-cancer Traduzir
DeepNews
$BGNE (BeiGene Ltd) BeiGene Ltd.’s Increase Of 0.03% Makes It Worthwhile To Consider Again BeiGene Ltd. (NASDAQ:BGNE) price on Friday, January 21, rose 0.03% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $251.45. A look at the stock’s price movement,... Mostrar mais Traduzir
VolatilityAlerts
$BGNE (BeiGene Ltd) share gains as it rises over 6.8%Traduzir
BGNE
BeiGene Ltd
224.30
-8.96 (-3.84%)
Negociar
Gostar ComentarPartilhar
null
.
DeepNews
$BGNE (BeiGene Ltd) BeiGene receives approval of supplemental new drug application for BRUKINSA in China BeiGene (BGNE) announced that the Center for Drug Evaluation of the China National Medical Products Administration ((NMPA)) has accepted a supplemental new drug application seekingalpha.com/news/3789503-beigene-receives-approval-of-supplemental-new-drug-application-for-brukinsa-in-china Traduzir